Novartis is again second in PharmExec’s 2012 ranking of the top 50 pharma companies based on Rx sales.
07:30 EDT 23 May 2012 | Novartis
This year's Pharm Exec 50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals.
Original Article: Novartis is again second in PharmExec’s 2012 ranking of the top 50 pharma companies based on Rx sales.
More From BioPortfolio on "Novartis is again second in PharmExec’s 2012 ranking of the top 50 pharma companies based on Rx sales."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
